Evidence map›Paper›PMID 40098896›Full record

ArticleHemaSphere2025

Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry.

Hyunyee Rosa Cho, Susanne Isfort, Kim Kricheldorf, Frank Stegelmann, Martine Klausmann, Florian H Heidel, Martin Griesshammer, Holger Schulz, Andreas Hochhaus, Joachim Göthert and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Hyunyee Rosa ChoDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine RWTH Aachen University, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) Aachen Germany.ORCID 0009-0004-9750-5554
Susanne IsfortDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine RWTH Aachen University, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) Aachen Germany.
Kim KricheldorfDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine RWTH Aachen University, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) Aachen Germany.
Frank StegelmannDepartment of Internal Medicine III University Hospital Ulm Ulm Germany.
Martine KlausmannGemeinschaftspraxis, Aschaffenburg Aschaffenburg Germany.
Florian H HeidelHematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH) Hannover Germany.
Martin GriesshammerUniversity Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden University of Bochum Bochum Germany.
Holger SchulzPractice for Clinical Hematology and Oncology Frechen Germany.
Andreas HochhausDepartment of Hematology and Oncology Jena University Hospital Jena Germany.
Joachim GöthertDepartment of Hematology, West German Cancer Center (WTZ) University Hospital Essen Essen Germany.
Rudolf SchlagHämatologisch-Onkologische Schwerpunktpraxis Würzburg Würzburg Germany.
Wiebke HollburgHOPA-Hämatologisch-Onkologische Praxis Altona Hamburg Germany.
Lino TeichmannDepartment of Medicine III University Hospital Bonn, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) Bonn Germany.ORCID 0000-0001-9489-7282
Katja SockelMedical Clinic and Policlinic I University Hospital Dresden, TU Dresden Dresden Germany.
Stefan WilopMVZ West GmbH Würselen, Hämatologie-Onkologie Würselen Germany.
Deniz GezerDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine RWTH Aachen University, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) Aachen Germany.
Martin KirschnerDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine RWTH Aachen University, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) Aachen Germany.
Konstanze DöhnerDepartment of Internal Medicine III University Hospital Ulm Ulm Germany.ORCID 0000-0002-2261-9862
Tim H BrümmendorfDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine RWTH Aachen University, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) Aachen Germany.
Steffen KoschmiederDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine RWTH Aachen University, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) Aachen Germany.ORCID 0000-0002-1011-8171
German Study Group for Myeloproliferative Neoplasms (GSG‐MPN)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40098896
PMCPMC11911930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.